Showing 2031-2040 of 9826 results for "".
Kamedis Botanically-based Regimen for Dandruff
https://practicaldermatology.com/topics/general-topics/kamedis-botanically-based-regimen-for-dandruff/18579/Kamedis brings innovation to the treatment of seborrheic dermatitis (SD, also called dandruff) with a botanically-based 2-step hair care system. The two-step Kamedis system for seborrheic dermatitis consists of SEBOMedis Anti-Dandruff Shampoo and Scalp Lotion. Botanical ingredients include indigo (IUV Risks, Cosentyx Update, ASDS Honorees
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-uv-risks-cosentyx-update-asds-honorees/18623/Teen indoor tanning may be linked with alcohol consumption in the past 30 days, marijuana use, and lifetime use of select illicit drugs, according to findings in JAMA Dermatology. L'Oréal unveiled My UV Patch this month at the Consumer Electronics Show. The stretchable skin sensor, to be introducedDr. Kauvar Discusses Experience with Gemini Laser
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/dr-kauvar-discusses-experience-with-gemini-laser/19469/“Treating with the Gemini is very well accepted by patients because both components of the Gemini, the 1064 and the 532nm, are non-invasive lasers. So there's really no real downtime and no recuperation, and the results are predictable in our hands, and patients are very satisfied with their treatDermwireTV — A big name is getting bigger; ICD-10 looms
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-mdash-a-big-name-is-getting-bigger-icd-10-looms/19163/In this premiere edition of DermWireTV, from the publishers of Practical Dermatology® magazine, we take a look at the latest acquisition by Valeant Pharmaceuticals, Inc., explore new data for Galderma's Mirvaso for rosacea, and get insights on the ICD-10 code set transition. #DermWireCurrent and Future Treatments
https://practicaldermatology.com/series/updates-vitiligo/current-and-future-treatments/26622/Dr. Karan Lal, a double board-certified adult and pediatric dermatologist and fellowship-trained cosmetic dermatologist with Affiliated Dermatology in Scottsdale, Arizona, talks with Practical Dermatology about the various options available today for repigmentation and treating flare-ups in vitiligoRecap of Maui Derm Hawaii Meeting
https://practicaldermatology.com/series/dermwire-tv/recap-of-maui-derm-hawaii-meeting/32717/In this week's DermwireTV, key stakeholders in dermatology gather in Hawaii to discuss the latest developments and advances; a new review examines whether IgE-targeting therapies could represent a new treatment avenue for psoriasis and atherosclerosis; and the founder of SEEN hair care joEmrosi Launched in the US for Rosacea
https://practicaldermatology.com/series/dermwire-tv/emrosi-launched-in-the-us-for-rosacea/33943/In this week's DermwireTV, a new treatment for rosacea is launched in the US; long-term data is presented for tapinarof 1% cream for atopic dermatitis; and in our C-Suite Chats segment, we speak with the CEO and Co-Founder of Mama Sol.Can Vitamin B3 Reduce Recurrence of NMSC?
https://practicaldermatology.com/topics/practice-management/can-vitamin-b3-reduce-recurrence-of-nmsc/21165/A common OTC vitamin supplement shows early promise in preventing secondary NMSCs. Is it time to recommend it?DermwireTV — Valeant Ups Allergan Bid, Nestle Buys Injectables, and Allergan Makes Its Case
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-mdash-valeant-ups-allergan-bid-nestle-buys-injectables-and-allergan-makes-its-case/19128/BREAKING NEWS: Valeant has increased its offer for Allergan to $72 per share. Read more. Valeant sells the rights to its aesthetic injectables to Nestle, while Allergan touts physician support and challenges Valeant's business model. In this week's edition of DermWireTV, learn about Valeant's latesFirst Cell-Based Gene Therapy for RDEB
https://practicaldermatology.com/series/dermwire-tv/first-cell-based-gene-therapy-for-rdeb/35742/In this week's DermwireTV, the FDA approves the first cell-based gene therapy for recessive dystophic epidermolysis bullosa (RDEB); a new acne scar treatment using focal point technology is cleared in the US; and in our “Updates on Skin Cancer” feature, we hear about the advantages of 40-GEP testing